Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own47.10% Shs Outstand14.75M Perf Week-58.42%
Market Cap23.35M Forward P/E- EPS next Y- Insider Trans4.13% Shs Float7.82M Perf Month0.10%
Income- PEG- EPS next Q-0.23 Inst Own0.01% Short Float / Ratio0.04% / 0.01 Perf Quarter-73.45%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.00M Perf Half Y-
Book/sh0.55 P/B2.88 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.40 P/C3.98 EPS next 5Y- ROE- 52W Range1.33 - 7.98 Perf YTD-78.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.20% Beta-
Dividend %- Quick Ratio6.99 Sales past 5Y0.00% Gross Margin- 52W Low18.80% ATR0.67
Employees- Current Ratio6.99 Sales Q/Q- Oper. Margin- RSI (14)36.04 Volatility25.07% 28.50%
OptionableNo Debt/Eq0.01 EPS Q/Q-48.08% Profit Margin- Rel Volume1.10 Prev Close1.81
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume202.21K Price1.58
Recom- SMA20-47.25% SMA50-47.63% SMA200-62.56% Volume223,177 Change-12.71%
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-21-23 10:42AM
Nov-20-23 08:00AM
07:23AM Loading…
Oct-26-23 07:23AM
Sep-18-23 08:30AM
Sep-05-23 08:31AM
Aug-31-23 08:31AM
Aug-29-23 11:39AM
Aug-09-23 09:35AM
Aug-03-23 02:40PM
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Baltimore, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cappy George10% OwnerAug 07Buy7.00119,048833,3362,859,318Aug 24 05:38 PM
Cappy George10% OwnerAug 02Buy7.00157,1701,100,1902,740,270Aug 04 01:42 PM